Archive for January, 2020

Cincinnati's thousand-pound toddler turns 3 years old this January, overcoming every obstacle thrown her way.Fiona the hippo will celebrate her third birthday this month. It's a big deal for the half-ton of pure hippo sass, considering she weighed a fifth of what a normal baby hippo should weigh when she was born Jan. 24, 2017."Fiona is remarkable for being unremarkable now," said Cincinnati Zoo curator of mammals Christina Gorsuch. "She's just like most other 2-year-old hippos, except for the fact that she's a celebrity in Cincinnati and beyond!"Fiona weighed 29 pounds when she was born, which is about 25 pounds lighter than the lowest recorded birth weight for this species. The normal range is 55-120 pounds.She has become an ambassador for her species and a great example of why zoos exist. She survived because of her animal care team's tireless efforts to save her and has inspired many to care about her species and wildlife, which is Cincinnati Zoo's mission.She now weights well over 1,000 pounds. Once Cincinnati's little baby, the hippo has reached a certain level of maturity as she nears three as her tusks begin to come in.But don't worry, Cincinnati. She's not old enough to date yet.She needs to be at least 5 before she starts thinking about boys, according to Wendy Rice, the head keeper at Cincinnati Zoo's Africa Department.And although she has hippo admirers across the country, Rice said Fiona is still a few years away from picking up a boyfriend.Of those hippo admirers, one such hippo is still laying it on thick. Timothy, a 3-year-old hippo from San Antonio, still pens Fiona weekly love notes on Facebook.But what ultimately will decide Fiona's potential future romance? It may not be cute love notes."The genetics are basically what's going to matter most," Rice said. "If and when Fiona were to get a breeding recommendation someday, it would be based entirely on who was genetically the best match for her -- that may or may not be Timothy."Fiona's genes are valuable in the world of Nile hippopotamuses. And eventually, Rice said the goal is to have Fiona breed if she can. But we're talking way down the road, when Fiona is at least 5 years old.What happens then?"We obviously don't want her going anywhere," Rice said. "We love her. She's our baby and this hometown loves her. We're fairly certain people would riot if we said Fiona was leaving. We're hopeful that if she gets a breeding recommendation, that a male would be brought here for her so she wouldn't have to leave Cincinnati."

Cincinnati's thousand-pound toddler turns 3 years old this January, overcoming every obstacle thrown her way.

Fiona the hippo will celebrate her third birthday this month. It's a big deal for the half-ton of pure hippo sass, considering she weighed a fifth of what a normal baby hippo should weigh when she was born Jan. 24, 2017.

"Fiona is remarkable for being unremarkable now," said Cincinnati Zoo curator of mammals Christina Gorsuch. "She's just like most other 2-year-old hippos, except for the fact that she's a celebrity in Cincinnati and beyond!"

Fiona weighed 29 pounds when she was born, which is about 25 pounds lighter than the lowest recorded birth weight for this species. The normal range is 55-120 pounds.

She has become an ambassador for her species and a great example of why zoos exist. She survived because of her animal care team's tireless efforts to save her and has inspired many to care about her species and wildlife, which is Cincinnati Zoo's mission.

She now weights well over 1,000 pounds. Once Cincinnati's little baby, the hippo has reached a certain level of maturity as she nears three as her tusks begin to come in.

But don't worry, Cincinnati. She's not old enough to date yet.

She needs to be at least 5 before she starts thinking about boys, according to Wendy Rice, the head keeper at Cincinnati Zoo's Africa Department.

And although she has hippo admirers across the country, Rice said Fiona is still a few years away from picking up a boyfriend.

Of those hippo admirers, one such hippo is still laying it on thick. Timothy, a 3-year-old hippo from San Antonio, still pens Fiona weekly love notes on Facebook.

But what ultimately will decide Fiona's potential future romance? It may not be cute love notes.

"The genetics are basically what's going to matter most," Rice said. "If and when Fiona were to get a breeding recommendation someday, it would be based entirely on who was genetically the best match for her -- that may or may not be Timothy."

Fiona's genes are valuable in the world of Nile hippopotamuses. And eventually, Rice said the goal is to have Fiona breed if she can. But we're talking way down the road, when Fiona is at least 5 years old.

What happens then?

"We obviously don't want her going anywhere," Rice said. "We love her. She's our baby and this hometown loves her. We're fairly certain people would riot if we said Fiona was leaving. We're hopeful that if she gets a breeding recommendation, that a male would be brought here for her so she wouldn't have to leave Cincinnati."

Excerpt from:
Fiona's greatest hits: 3 years of sassy hippo bliss - WLWT Cincinnati

The clotting disorder hemophilia A may become the third gene therapy that the US Food and Drug Administration approves, joining treatments for a form of retinal blindness in 2017, and spinal muscular atrophy in 2019.

Biomarin Pharmaceutical Inc. has submitted a biologics license application to FDA and documentation of clinical trial results to the European Medicines Agency, with reviews slated to begin early this year at both organizations.

An article in the January 2 New England Journal of Medicine from a UK research team presents the findings of a phase 3 analysis of continuing success of a phase 1/2 trial (instead of a new phase 3 trial). The hemophilia gene therapy called valoctocogene roxaparvovec for now can mean a one-time infusion that replaces the more than 100-150 infusions of clotting factor a patient takes each year, and can also alleviate the painful joint bleeding that is the hallmark of the disease.

The different clotting disorders result from mutations in different genes in the pathway that knits a clot from protein fibrils. Hemophilia A is a deficiency of clotting factor VIII, and is also called classic hemophilia. It accounts for 80 percent of people with the disease. The clotting disorder that threaded through the royal families of Europe was hemophilia B, which is a deficiency of factor IX.

Both hemophilias are transmitted by genes on the X chromosome, and therefore affect only males. One in 10,000 males has hemophilia A, and it arises as a new mutation (rather than being inherited), in about a third of cases.

The world focused on hemophilia A with the sad case of Ryan White. Born in 1971, Ryan was diagnosed at 3 days of age when his circumcision wound wouldnt stop bleeding.

Like many people with hemophilia A at the time, Ryan received weekly factor VIII pooled from donors. That would prove tragic, as President Reagan was late to the game of testing the blood supply for viruses. He refused to even utter the word AIDS until actor Rock Hudson died of it in 1985.

That was too late for Ryan White.

HIV as the cause of the mysterious new epidemic was identified in 1983, although for a time it was known by different names.

In 1984, Ryan had a lung biopsy to diagnose severe pneumonia that revealed that he was HIV positive. Nearly 90% of people with hemophilia who received clotting factors from pooled donor blood between 1979 and 1984 contracted HIV and/or hepatitis C.

Ryan survived longer than predicted, until the end of 1990. In the intervening years he catalyzed AIDS activism when he was denied admittance to school, and he and his family fought the discrimination and ignorance.

Hemophilia A gene therapy has been twenty years in the making.

By the end of the decade that began with Ryan Whites death, the first gene therapy for hemophilia A was being tested in a clinical trial in Pittsburgh. I was fortunate to interviewthe first patient soon after he received the gene therapy.

Like Ryan White, Don Miller had nearly bled to death when he was circumcised. He recalled other frightening incidents.

I fell at my grandmothers house and had a one-inch-long cut on the back of my leg. It took five weeks to stop bleeding. It leaked slowly, so I didnt need whole blood replacement. But if I moved a little the wrong way, it would open and bleed again.

Millers treatments paralleled the history of countering hemophilia, from whole blood infusions, to plasma replacement, to cryoprecipitate (a frozen plasma product containing clotting factors). Then he injected pooled factor VIII three times a month. But somehow he never contracted HIV, and thats what got him into the gene therapy clinical trial.

I lucked out, Miller told me. Besides his good fortune at dodging the HIV bullet, he was in the right place at the right time. Hed been a librarian at the University of Pittsburgh, where the clinical trial was to take place.

On June 1, 1999, Don Miller received the first of three injections of retroviruses engineered to carry factor VIII. Chiron Corp., one of the original wave of big biotech companies that was absorbed into Novartis in 2006, designed and manufactured the vector.

The goal of this first round of hemophilia A gene therapy wasnt to cure the disease, but to boost factor VIII levels a scant 2 to 7 percent, which was expected to dampen bleeds.

Don Miller hadnt had any side effects when I spoke with him, but I dont know how he fared. At the time, he spoke freely to the media, but I contacted his physician and she couldnt provide an update due to HIPAA regulations.

But that first hemophilia A gene therapy was safe. Some patients had transient increases in factor VIII, and for 5 of the 13, bleeds became less frequent.

When the gene therapy field emerged from several setbacks that began with the death of Jesse Gelsinger in 1999, the hemophilia strategy changed to a safer and more efficient vector. The clinical trial leading to the current FDA submission began with 15 patients who received the factor VIII gene delivered in adeno-associated virus serotype 5, starting in June 2015. A year later, 13 of the men treated with a single infusion had normal or near-normal levels of factor VIII.

The AAV5 vector coaxes greater expression of the gene than does the retrovirus used in the earlier trial. Plus, an added bit of control DNA (a promoter) directs the vector to the types of cells that normally make the factor in the liver and to white blood cells.

AAV5s capacity is only about 4,700 DNA bases, so the big factor VIII gene is trimmed a bit (as it was for the earlier trial too). Still, it had to be delivered in two viral shipments, with some assembly required, like sending a cell phone and its charger in separate Amazon prime boxes.

Unlike other vectors (lentivirus and retroviruses), AAV remains separate from the cells chromosomes, forming a DNA circle called an episome.

Two of the 15 patients received doses too low (6 or 20 trillion viruses per kilogram of body weight) to have an effect. But six men receiving an intermediate dose of 40 trillion viruses had no bleeding events; the annual number of needed factor VIII infusions for the three-year study period fell from 155 to 0.5, and only one man had a bleed in a large joint.

The high-dose (60 trillion viruses) men did the best: none required factor VIII infusions, bleeding events, or large joint bleeds.

Analysis of factor VIII levels and various biomarkers of the gene indicated that of the 13 men who responded, one is considered to no longer have hemophilia, eleven have mild disease, and one has moderate disease.

It all adds up to what the researchers call a sustained, clinically relevant benefit. Said lead author John Pasi, from the Royal London Haemophilia Centre, Barts Health NHS Trust:

Our 2017 paper showed that gene therapy could significantly boost factor VIII levels in men with hemophilia A. Our new data are critical in helping the scientific and medical communities understand this pioneering technology. This latest study confirms both safety and long-term beneficial impact. A long-term treatment that effectively ends the life-long regular injections can transform care and massively improve the quality of life of hundreds of thousands of people born with this challenging genetic condition.

Once an advisory committee to FDA agrees, valoctocogene roxaparvovec will debut with a catchier brand name. It may cost in the $400,000 to $1 million range (or higher) of other gene therapies in the US and Europe, but considering that current therapies for hemophilia A are about $270,000 annually without complications and can exceed $1 million if there are, a one-and-done gene therapy for hemophilia A sounds like a good deal.

Ricki Lewis is the GLPs senior contributing writer focusing on gene therapy and gene editing. She has a PhD in genetics and is a genetic counselor, science writer and author of The Forever Fix: Gene Therapy and the Boy Who Saved It, the only popular book about gene therapy. BIO. Follow her at her website or Twitter @rickilewis

Read the rest here:
Will 2020 see the debut of promising gene therapy for hemophilia A? It's up to the FDA. - Genetic Literacy Project

Oil giant BP (LON:BP) sprung a surprise on Tuesday (January 7) by announcing the sale of some of its iconic North Sea assets to Premier Oil (LON:PMO), one of the U.K.'s most indebted oil and gas companies.

The deal worth 474 million ($625 million) will see a package of North Sea assets, including the Andrew platform and BP's controlling stake in five surrounding fields, as well as its minority stake in the Shell-operated Shearwater field, transferred to Premier Oil.

The five fields - Andrew, Arundel, Cyrus, Farragon and Kinnoull - all produce via the Andrew platform, which is about 140 miles (225km) north east of Aberdeen, and has been run by BP since 1994, coming onstream in 1996. The oil giant's minority stake in the Shell-operated Shearwater field stands at 27.5%.

The Andrew platform and BP's controlling stake in five surrounding fields, as well as its minority ... [+] stake in the Shell-operated Shearwater field will be sold to Premier Oil.

BP said the move was aimed at "reshaping" its North Sea asset portfolio under an ongoing 7.6 billion divestment program.

The sale marks a continuing trend of North Sea divestments by BP. In 2017, it sold its interests in the Bruce, Keith and Rhum fields to Serica Energy for 300 million. Earlier that year, the oil giant also sold its Forties Pipeline System (FPS) to Ineos in 250 million deal. The 235-mile pipeline system, which links 85 North Sea oil and gas assets belonging to 21 companies, was first opened in 1975.

BP is by no means alone in divesting mature North Sea assets. Rival Royal Dutch Shell (LON:RDSB) sold half of its U.K. production base to private equity-backed Chrysaor the same year as BP sold the FPS, and other majors such as Chevron (NYSE:CVX) and ConocoPhillips (NYSE:COP) have also divested from the region.

Ariel Flores, North Sea regional president at BP, said: "BP has been reshaping its portfolio in the North Sea to focus on core growth areas. As a result of this focus, we have also now decided to divest our Andrew and Shearwater interests, believing them to be a better strategic fit for another owner.

"We are confident that Premier Oil, already a significant operator in the North Sea, is the right owner of these assets as they seek to maximize their value and extend their life."

The midcap buyer of BP's assets is one of the most indebted oil companies in the U.K. with a debt pile of 1.5 billion. But Premier Oil said it would be paying for the assets via combination of existing cash, an acquisition bridging facility of 228 million and a fresh equity raise of 380 million.

Tony Durrant, Chief Executive of Premier Oil, said: "These acquisitions are in line with our stated strategy of acquiring cash generative assets in the UK North Sea.

"We look forward to realizing the significant long-term potential of the Andrew and Shearwater assets through production optimization, incremental developments and field life extension projects."

A total of 69 BP staff working on the divested assets are expected to move to Premier Oil. Following announcement of the divestment, as of 12:07 GMT on Tuesday, BP's shares were trading down 0.93% or 4.70p in London at 499.40p, while Premier Oil's were up 16.81% or 17.05p at 118.71p.

See the original post:
BP Agrees To $625 Million Sale Of North Sea Assets With One Of U.K.s Most Indebted Oil Companies - Forbes

Growing emphasis on the food safety and longer shelf life has played an important role in the development of ingredients that aid in food preservation. These ingredients vary from simple water content to salt or sugar to chemicals like antioxidants and are used to prevent growth of microorganisms, thereby delaying the spoilage process. In terms of origin, food safety and shelf life extension ingredients can be synthetic or natural in nature.

Food preserving ingredients have been an integral part of kitchen aisles in the form of lemon, ginger, vinegar, spices, salt and sugar. Their traditional utilization was replaced by synthetic ingredients with increasing commercialization of the food industry in past decades. However, with the dissemination of knowledge related to harmful effects of synthetic ingredients, currently, the industry is witnessing a prominent shift toward natural ingredients for food safety and shelf life extension.

Shelf Life Extension Ingredients Market Notable Developments

Get Special Discount on this Report @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=4578

Shelf Life Extension Ingredients Market Dynamics

Clean-Label Trend Fuels Synthetic to Natural Transition in Food Ingredient Landscape

Naturally sourced ingredients have gained significant traction as consumer preference for natural products continues to surge. In terms of effectiveness, natural preservatives are superior in delivering greater protection and longer shelf life. As they work with equivalent efficiency and are healthful in nature, adoption of naturally sourced ingredients is increasing consistently as compared to the synthetic options.

Natural ingredients such as antimicrobials or antioxidants have additional potential health benefits also. Well aware of the increasing consumer demand for natural food products that are without artificial ingredients, manufacturers in the food ingredient market are introducing bio-based or naturally sourced food safety ingredients.

Frozen Foods Drive Demand for Specialized Food Safety Ingredients

Ranging from salads to sauces or ready meals to rice, a plethora of food products are available in frozen forms. As the demand for fresh and frozen foods increase across the globe, food manufacturers are seeking innovative ways to introduce novel food safety ingredients to extend the shelf life of frozen foods.

Manufacturers in the food safety and shelf life extension ingredient market are introducing ingredients specific to refrigerated products. Along with providing safety, these ingredients are label friendly and help in reducing sodium content while enhancing consumers sensory experience.

Shelf Life Extension Ingredients Market Regional Outlook

North America presents lucrative opportunities for the Shelf Life Extension Ingredients Market on the back of buoyancy in regions the food and beverage industry and presence of leading F&B companies.

The market is likely to witness increasing opportunities in the developing countries of Asia pacific. These countries are witnessing huge demand for frozen foods, RTD food and beverages and processed food, thereby presenting higher potential for the market in the future.

Shelf Life Extension Ingredients Market Segmentation

The Shelf Life Extension Ingredients Market is segmented into following,

Based on type, Shelf Life Extension Ingredients Market can be segmented in,

Based in function, Shelf Life Extension Ingredients Market can be segmented in,

Based on application, Shelf Life Extension Ingredients Market can be segmented in,

Request TOC for Facts & Tables @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=4578

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,3739 Balboa St # 1097,San Francisco, CA 94121United StatesTel: +1-415-520-1050

Read more:
Shelf Life Extension Ingredients Market Competitive Landscape Analysis with Forecast by 2028 - BulletintheNews

Anki, which shuttered in April after burning through almost $200 million in venture capital financing, could have a new lease on life or a life extension, at least. As first spotted by The Verge, Pittsburgh-based educational tech startup Digital Dream Labs this week announced it will pick up development of Vector, Ankis most recent robot, in the coming months.

Digital Dream Labs plans to kick off a Kickstarter campaign to fund the launch of two new products for Vector owners. The first an Escape Pod will enable the robot to work offline sans internet connection to Ankis cloud datacenters, while the second an open source development kit and a custom bootloader will allow Vector owners to create and make available new features and functionality.

The most important part of this update is to let you know we have taken over the cloud servers and are going to maintain them going forward, wrote Vector CEO Jacob Hanchar in a blog post. This is just the beginning and subject to change, but because you have shown such loyalty and got this project off the ground in the first place, I felt it was necessary to communicate these developments as soon as possible!

Anki, the San Francisco startup behind AI-imbued robotics toys like Overdrive, and Cozmo as well as Vector, shut down immediately after laying off its workforce of just over 200 people. A failed round of financing was reportedly to blame. CEO Boris Sofman told employees that a deal failed to materialize at the last minute, as did acquisition interest from companies such as Microsoft, Amazon, and Comcast.

Anki claimed to have sold 6.5 million devices total, and 1.5 million robots last August alone. (Cozmo was the top-selling toy on Amazon in 2017 with a community of more than 15,000 developers.) And in fall 2018, the company revealed that revenue was close to $100 million in 2017, a figure it expected to beat the subsequent year.

Anki, which was founded by Mark Palatucci, Sofman, and Hanns Tappeiner in 2010 with the mission of bring[ing] artificial intelligence and robotics into [users] daily lives, made a splash six years ago with its smartphone-controlled car setAnki Drive(alternatively Anki Overdrive), which was demonstrated onstage at Apples 2013 WorldWide Developer Conference. Anki later became an Apple retail partner and introduced several Overdrive accessories, including a series with Hot Wheels branding.

Cozmo a cute robot toy that made use of Ankis companys deep artificial intelligence research and team of Pixar and Dreamworks animators debuted in October 2016, ahead of Vector. But despite their novelty and sophistication, the robots shared relatively high launch price points ($180 for Cozmo and $249 for Vector), which likely contributed to their slow uptake in the notoriously unforgiving consumer robotics space.

Ankis closure followed the shuttering of Bosch-backed startup Mayfield Robotics, which was developing a larger, pricier ($700) home robot dubbed Kuri. Robotics companyJibo, which engineered a social robot featuring a bespoke conversational assistant, shut down earlier this year. In somewhat related news, industrial robotics companyRethink Roboticsclosed its doors seven months ago after attempting unsuccessfully to find an acquirer.

See more here:
Digital Dream Labs will revive shuttered startup Ankis Vector robot - VentureBeat

A terminally ill childs death should not be determined by a panel of doctors and a judge. Parents should have a say in the decision to maintain life-extending care. But in Texas, Fourth District Court of Appeals Chief Justice Sandee Bryan Marion went along with the determination of doctors at Cook Childrens Medical Center in Fort Worth to pull life support from 11-month-old Tinslee Lewis, despite her familys wishes to keep her alive.

The Jan. 2 ruling was made based on arguments during a Dec. 12, 2019, hearing. Tinslee Lewiss family intends to appeal the decision.

Tinslee was born in February 2019 with a host of medical ailments. She was premature and suffered from Ebsteins anomaly, a serious heart defect, chronic lung disease, and high blood pressure. Tinslee has been breathing with the help of a ventilator since July, when she went into respiratory arrest, and is deeply sedated and medically paralyzed. Her mother, Trinity Lewis, maintains hope.

Doctors in Texas possess the legal right to determine when a patients life ends because of the Texas Advanced Directives Act, passed in 1999. The law requires that before physicians can terminate life support, an ethics or medical committee must vet their decision. The patient is informed at least 48 hours in advance about the meeting to end his life, and receives the information in writing. The patient and his family then have 10 days to transfer to a facility where he wont be removed from life support, should he so desire.

After an October Ethics Committee meeting, doctors at the Cook Childrens Medical Center invoked the 10-day rule, wherein they determined they can remove life support, regardless of what the patients family wants. In this case, Tinslees mother desperately wants her baby to live.

A temporary restraining order was filed to prohibit the removal of care, but it expired Dec. 10. The family tried to find a different facility that wouldnt remove Tinslee from life support, but none could offer further life extension, and the case went to court for a temporary injunction hearing Dec. 12.

Typically, the process of ending life-extending care does not reach the court system. Families and doctors are usually able to come to an agreement about the best course of action, which is especially difficult for a mother to a baby who hasnt even reached her first birthday. If the family cannot find adequate placement for their loved one, the hospital may cease life-extending care. Lewis is trying to keep Cook Childrens from terminating Tinslees ventilator while the mother seeks an appeal of Judge Marions decision.

Texas Right to Life advocates for continuing care, and Fort Worth Catholic Diocese Bishop Michael F. Olson has offered to help obtain care for Tinslee at a Catholic hospital. Texas Gov. Greg Abbott and Attorney General Ken Paxton issued a joint statement saying, The state will continue to support Ms. Lewis exhaustion of all legal options to ensure that Tinslee is given every chance at life. The AGs office said it would ensure Tinslees right to life all the way to the Supreme Court.

After Marions ruling, the doctors released a statement that said, Our medical judgment is that Tinslee should be allowed to pass naturally and peacefully rather than artificially kept alive by painful treatments. Even with the most extraordinary measures the medical team is taking, Tinslee continues to suffer. To keep her alive, doctors and nurses must keep her on a constant stream of painkillers, sedatives, and paralytics.

The statement continued, As a result, Tinslee is paralyzed at all times. She currently is suffering from severe sepsis, not uncommon when patients require deep sedation and chemical paralysis to maintain organ function. Even with medication and support, Tinslee has dying events 2-3 times per day. When she is in distress, Tinslee crashes and aggressive medical intervention is immediately necessary, which causes even more pain.

Tinslees mother spoke with dismay after the ruling, saying she is heartbroken over todays decision because the judge basically said Tinslees life is NOT worth living. I feel frustrated because anyone in that courtroom would want more time just like I do if Tinslee were their baby. I hope that we can keep fighting through an appeal to protect Tinslee. She deserves the right to live. Please keep praying for Tinslee and thank you for supporting us during this difficult time.

The case is reminiscent of Charlie Gards story. Gard was born in the U.K. with a need for life-extending care. While his parents were hopeful and medical professionals outside the U.K. offered alternative care to that from the National Health Service, Gards doctors declined to let his parents take him elsewhere. While this is extreme, it is not too far on the horizon for the U.S. health care system once doctors and judges can determine a patients fate rather than the patient or their families.

Tinslees doctors argue that she is in pain and this suffering is reason enough to allow her life to end. But determining the value of a life based on the perceived suffering of that person who cannot speak, and whose family wants desperately to keep her alive, is a mistake. While older, terminally ill patients at the end of their lives have more options and have had a lifetime to decide what they would choose when the worst comes to pass, the consideration for the youngest among us must be different. Parents should be the people responsible for making those determinations, and if courts and doctors can take that power away, there are risks for all of us who enter the medical system.

Not long ago in the United States, hospitals provided no care for premature babies. The majority of American hospitals had nothing to help them. No technology, no special skills. There was no central heat to keep them warm. Doctors would place heated bricks in cribs and cross their fingers, said reporter Katie Thornton in an episode of 99% Invisible.

Treatment for premature babies didnt begin to change until a doctor in France came up with the idea to house premature babies in something like the incubators used to hatch chickens. The life-saving incubators were not even adopted in hospitals, but first featured as part of a sideshow exhibit at the Omaha Worlds Fair and other fairs, hawked on the midway.

Instead of bringing preemies to hospitals, parents would bring them to the fair and hope for the best. These incubators turned out to be the most substantial treatment innovation for premature babies. It was still decades before hospitals adopted the idea and turned it into the concept of the neonatal intensive care unit, or NICU.

Why, now that doctors can do so much, are they turning their backs on the patients that need them most, and saying its for their own good? Is it ever compassionate to end a human life if it can be saved or extended, especially in cases where the person is not capable of consent? Tinslees mother is hoping for a miracle. In the absence of that, Trinity Lewis would like just a little more time with her daughter. No judge, doctor, or law should stand in the way of that.

Read the original:
Judges Shouldn't Have More Power Over Tinslee Lewis Than Her Mother - The Federalist

BP has agreed terms to sell its interests in the Andrew area in the central UK North Sea and its non-operating interest in the Shearwater field.

Under the terms of the deal, Premier Oil will pay BP USD 625 million.

BP has been reshaping its portfolio in the North Sea to focus on core growth areas, including the Clair, Quad 204 and ETAP hubs. Were adding advantaged production to our hubs through the Alligin, Vorlich and Seagull tieback projects, Ariel Flores, BP North Sea regional president, said. As a result of this focus, we have also now decided to divest our Andrew and Shearwater interests, believing them to be a better strategic fit for another owner. We are confident that Premier Oil, already a significant operator in the North Sea, is the right owner of these assets as they seek to maximise their value and extend their life.

The five fields in the Andrew area all produce through the Andrew platform, which is located about 140 miles north-east of Aberdeen. The hub started production in 1996. In 2019, average daily production has been around 25,000 to 30,000 barrels of oil equivalent per day.

The Shearwater field is a high pressure, high temperature reservoir produced through a process, utilities and quarters platform, located around 140 miles east of Aberdeen. Shearwaters 2019 production has been in the region of 14,000 barrels of oil equivalent per day gross.

The Andrew assets are expected to transition to Premier Oil as a fully operational entity with 69 staff who operate and support the assets. Their contractual terms and conditions are protected under UK Transfer of Undertakings (Protection of Employment) Regulations (TUPE). BP will now begin consultation with in-scope staff.

There is no transfer of staff associated with the Shearwater sale.

The sales are the latest step in BPs planned programme of USD 10 billion divestments by the end of 2020. Subject to the receipt of regulatory and other third-party approvals, BP aims to complete the sale and transfer of operatorship of the assets at the end of the third quarter of 2020.

The deal includes BPs operating interests in the Andrew area comprising the Andrew (62.75%), Arundel (100%), Cyrus (100%), Farragon (67%) and Kinnoull (77.06%) assets as well its non-operating 27.5% interest in the Shell-operated Shearwater.

Premier Oil confirmed the proposed acquisitions of the Andrew Area and Shearwater assets from BP, and an additional 25 per cent. interest in the Premier operated Tolmount Area from Dana for USD 191 million plus contingent payments of up to USD 55 million (together the Acquisitions). Premier also announced the proposed extension of its existing credit facilities to 30 November 2023.

The proposed acquisitions will be funded via a USD 500m equity raise (net of expenses) which has been fully underwritten on a standby basis, existing cash resources and, if required, an Acquisition Bridge Facility of USD 300 million. Premier expects that the equity raise will include both a placing and rights issue component with any shares issued under the placing qualifying for the subsequent pre-emptive rights issue. It expects to confirm the structure and terms in Q1 2020 following consultation with major shareholders.

Lender consent for the proposed acquisitions, related funding arrangements and extension of credit facilities will be sought via two Court-approved schemes of arrangement (the Schemes). Of the creditors subject to the Schemes, 83.3 per cent. of Super Senior Commitments and 72.7 per cent. of the Senior Commitments have already committed to approve the Schemes.

The Andrew and the Shearwater Acquisitions constitute a class 1 transaction. Shareholder approval for all of the acquisitions and the equity raise will be sought at a general meeting expected to be held in Q1 2020. The Directors believe that the acquisitions represent a highly attractive opportunity and recommend that Premiers shareholders vote in favour of the resolutions, as the Directors intend to do in respect of their holdings, at the general meeting. Premier Oil will send a combined prospectus and circular to its shareholders convening the general meeting in due course.

The acquisitions have an effective date of 1 January 2019 and completion of all three acquisitions is expected to occur by the end of Q3 2020.

These acquisitions are materially value accretive for Premier Oil and are in line with our stated strategy of acquiring cash generative assets in the UK North Sea. We look forward to realising the significant long-term potential of the Andrew and Shearwater assets through production optimisation, incremental developments and field life extension projects. We are also pleased to have consolidated our interest in the high return Tolmount development where we see material upside. The cash flow generated from the acquired assets will also accelerate the deleveraging of Premiers balance sheet, Tony Durrant, Chief Executive, commented.

More here:
BP to sell North Sea Interests in Andrew Area and Shearwater to Premier Oil - Energy Industry Review

Tony Durrant: deals in line with stated strategy

Premier Oil has unveiled three acquisitions in the North Sea worth $871m as it seeks to consolidate assets in the region.

It is acquiring the Andrew Area and Shearwater assets from BP for $625 million, and an additional 25% interest in the Premier-operated Tolmount Area from Dana for $191m plus contingent payments of up to $55m.

Premier has announced the proposed extension of its existing credit facilities to 30 November 2023.

It said the acquired assets will generate more than $1 billion of free cash flow to end 2023

The proposed acquisitions will be funded via a $500m equity raise (net of expenses) which has been fully underwritten on a standby basis, existing cash resources and, if required, an acquisition bridge facility of $300 million.

Premier expects that the equity raise will include both a placing and rights issue. It expects to confirm the structure and terms in Q1 2020 following consultation with major shareholders.

The three acquisitions are expected to complete by the end of Q3 2020.

Tony Durrant, chief executive, commented: These acquisitions are materially value accretive for Premier and are in line with our stated strategy of acquiring cash generative assets in the UK North Sea.

We look forward to realising the significant long-term potential of the Andrew and Shearwater assets through production optimisation, incremental developments and field life extension projects.

We are also pleased to have consolidated our interest in the high return Tolmount development where we see material upside. The cash flow generated from the acquired assets will also accelerate the deleveraging of Premiers balance sheet.

Continued here:
Premier in $871 million swoop on North Sea assets - Daily Business

Antioxidants are used as vitamin supplements in pharmaceutical industry and help in preserving food products. The global Antioxidant Supplement market is poised to witness significant growth during the forecast period owing to decrease in their costs, increase in investment & product approval by regulatory authorities, and increase in their demand in the food & beverage industry. In addition, developed economies have discovered new growth opportunities by shifting their focus on natural antioxidants such as rosemary extract.

Get Sample copy of this Report @: http://www.a2zmarketresearch.com/sample?reportId=117562

Top Companies profiled in this Report includes: NOW, Vibrant Health, AST R-ALA, GNC, Jarrow Formulas, Life Extension.

The global Antioxidant Supplement market is analyzed in terms of its competitive landscape. For this, the report encapsulates data on each of the key players in the market according to their current company profile, gross margins, sale price, sales revenue, sales volume, product specifications along with pictures, and the latest contact information. The reports conclusion leads into the overall scope of the global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the global Antioxidant Supplement market in the near future.

The report gathers the essential information including the new strategies for growth of the industry and the potential players of the global Antioxidant Supplement Market. It enlists the topmost industry player dominating the market along with their contribution to the global market. The report also demonstrates the data in the form of graphs, tables, and figures along with the contacts details and sales of key market players in the global Antioxidant Supplement Market.

Global Antioxidant Supplement Market Segmentation:

Product Type Segmentation:

Medical GradeFood Grade

Industry Segmentation:

MedicalFoodCosmetics

Get Upto 30% Discount on first Purchase of this report @: http://www.a2zmarketresearch.com/discount?reportId=117562

The regions which are covered in this report are North America, Europe, Asia Pacific, Middle East & Africa and Latin America. Considering the given forecast period and precisely studying each and every yearly data, a report is been drafted to ensure the data is as expected by client.

Influence of the Antioxidant Supplement Market report:

For More Information, Inquire @: http://www.a2zmarketresearch.com/enquiry?reportId=117562

Table of Contents

Global Antioxidant Supplement Market Research Report 2020-2025

Chapter 1 Antioxidant Supplement Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Antioxidant Supplement Market Forecast

If you have any special requirements, please let us know and we will offer you the report as you want.

Read more from the original source:
Growing Demand of Antioxidant Supplement Market by 2025 with Top Key Players- NOW , Vibrant Health , AST R-ALA , GNC , Jarrow Formulas -...

BILLINGS Thirty-three Yellowstone bison that had been held in quarantine including 14 females with calves were shipped from their pasture near Gardiner to the Fort Peck Indian Reservation on Dec. 23.

It was an early Christmas present for the tribes.

Im really happy, said Robert Magnan, the tribes bison manager. Were not only taking females and babies, some of the females are pregnant. Its a double batch.

The female bison are the first Yellowstone descendants to leave since a 2014 release of 138 bison that had been quarantined on one of Ted Turners Montana ranches for nearly a decade. They are also the first female bison to be released under a new agreement between tribes, state and federal agencies.

Defenders of Wildlife, a conservation group that paid for the bison to be hauled, hailed the transfer as a sign of increased cooperation between the organizations, as well as an example of how a nonprofit can help out.

This pipeline is starting to happen, said Chamois Andersen, Defenders senior representative for bison.

Although only a trickle now, the group is hoping that the movement of animals will prove to officials that the Fort Peck Tribes can be more engaged in the quarantine and testing of bison, Andersen said. Reaching such a goal would chip away at the number of Yellowstone bison sent to slaughter.

In 2019, more than 300 Yellowstone bison were shipped to slaughter after being captured by park workers. The bison are trucked to slaughter facilities in Montana where they are killed and butchered. The meat is shared among cooperating tribes. Yellowstone officials would like to reduce the number of bison killed in this manner but are constrained by the number of animals the park can hold in quarantine.

The park is collaborating with the Animal Plant Health Inspection Service, a federal agency, to optimize available space for quarantined bison, according to Yellowstone spokeswoman Morgan Warthin. APHIS has been using a Corwin Springs pasture to hold bison for brucellosis testing, including Mondays cohort. Warthin wouldnt say whether that pasture would be available to the park to hold bison in quarantine. Fifty-eight bison remain at the facility, according to an APHIS spokesperson.

Female bison face stricter regulations for release because, if infected with the disease brucellosis, their birthing materials are considered the main means of spreading infection. Consequently, immature female bison must test negative for exposure to brucellosis for 2 1/2 years before they can be shipped to join other herds.

We know females are the most scrutinized, Andersen said. And we couldnt do it without APHIS. They are the most concerned about state management and what this program will look like.

Upon arrival at the reservation, the 33 animals trucked on Monday will be quarantined from the tribal commercial herd on the Fort Peck Reservation for another year while being tested again for brucellosis.

The 5- to 8-year-old bison shipped on Monday, which included five bulls, also includes the 14 calves born in the Corwin Springs pasture used by APHIS. The adults have been quarantined since December 2017 or June 2018. Although the Fort Peck Tribes built its facility to meet quarantine requirements, the state of Montana has denied requests to use the corral for anything other than the last assurance test.

Nevertheless, the tribes have steadily built a cultural herd that numbers 400 head as well as a separate commercial herd.

Were at our carrying capacity right now, Magnan said of the cultural herd.

In July, after the calving season, the tribes plan to ship a portion of its herd to the InterTribal Buffalo Council for disbursement. This past June, the tribes shipped five bison to the Wind River Reservation in Wyoming as it builds its buffalo herd.

Yellowstone bison are highly prized by tribes as well as bison ranchers and managers of other conservation herds for their pure genetics, meaning they have never been interbred with cattle.

View original post here:
Female Yellowstone bison shipped to tribes - The Spokesman-Review

Behnam Kamalidehghan,1,* Mohsen Habibi,2,* Sara S Afjeh,1 Maryam Shoai,3 Saeideh Alidoost,4 Rouzbeh Almasi Ghale,4 Nahal Eshghifar,5 Farkhondeh Pouresmaeili1,6

1Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Central Laboratory, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; 4Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; 5Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran and Mens Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 6Mens Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*These authors contributed equally to this work

Correspondence: Farkhondeh PouresmaeiliMens Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranTel/Fax +98 21-23872572Email pouresfar@gmail.com

Background: MicroRNAs (miRNA) play a key role in the regulation of gene expression through the translational suppression and control of post-transcriptional modifications.Aim: Previous studies demonstrated that miRNAs conduct the pathways involved in human reproduction including maintenance of primordial germ cells (PGCs), spermatogenesis, oocyte maturation, folliculogenesis and corpus luteum function. The association of miRNA expression with infertility, polycystic ovary syndrome (PCOS), premature ovarian failure (POF), and repeated implantation failure (RIF) was previously revealed. Furthermore, there are evidences of the importance of miRNAs in embryonic development and implantation. Piwi-interacting RNAs (piRNAs) and miRNAs play an important role in the post-transcriptional regulatory processes of germ cells. Indeed, the investigation of small RNAs including miRNAs and piRNAs increase our understanding of the mechanisms involved in fertility. In this review, the current knowledge of microRNAs in embryogenesis and fertility is discussed.Conclusion: Further research is necessary to provide new insights into the application of small RNAs in the diagnosis and therapeutic approaches to infertility.

Keywords: miRNA, female fertility, male fertility, piwi-interacting RNAs, piRNAs

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Original post:
The Importance of Small Non-Coding RNAs in Human Reproduction: A Revie | TACG - Dove Medical Press

Mike goes to ScotlandAttending the Royal Highland Show in Edinburgh, Scotland, was an opportunity to observe cattle and beef programs unique to the United Kingdom. Cattle tend to be taller, well-muscled with less marbling than Canadian cattle. But thats to be expected as they compete against cattle in the EU. Many heifers calve as three-year-olds, giving them more size before they calve. But a few cattle producers I spoke with were looking at calving their heifers at 2.5 years.The hospitality of the Scottish Simmental Society and all breeds I visited with was second to none. I noted that agriculture is very important to consumers in the U.K. They know what its like for food to be scarce, especially since the countrys experience during the last World War. There were no midways or carnivals at the Royal Highland Show but more urban crowds than what we would see here. They all wanted to know where their food came from and were actively engaged in learning more.

One of the exhibitors we visited with at the show was Neil McGowan of Incheoch Farm. Neil, along with his wife Debbie, son Angus and daughter Tally run Incheoch Farm near Alyth up in the Perthshire hills. I had initially met McGowan in the fall of 2018 when he and Debbie were touring cattle operations in Saskatchewan and Alberta looking for Canadian genetics that would work for their herd back in Scotland. McGowans travels also included Canadian Western Agribition and Farmfair International to see the latest genetics and arrange farm visits with Canadian seedstock producers.

Their farm runs 220 cows and 1,100 sheep. The cattle herd is made up of Simmental and Luing breeds. Luing is a native Scottish breed made up of Shorthorn and Simmental. They sell approximately 20 bulls and 100 rams in their Working Genes on-farm auction sale. The cattle at McGowans farm were impressive as they were well-muscled and the kind of cattle that would work well in Canada. McGowan has a passion for breeding better livestock as referenced by his paper Selection for Efficiency: Breeding Better Beef and Sheep. This paper was a report written as part of his Nuffield Farming Scholarship back in 2016. Part of McGowans research included looking at livestock operations in Canada, the U.S., New Zealand, Australia and parts of the U.K.

Some of McGowans key conclusions included having consistent breeding goals based on profitability, with feed efficiency also playing a part in the profitability equation. In the U.K. as in Canada fertility, longevity and cow size all play a role in improving efficiency.

McGowan family (l. to r.): Finlay, Neil, Debbie, Angus, Judy and Donna Asher.photo: Mike Millar

After a great day taking in a little Scottish mist and walking pastures sorting through a lot of very good cattle, I had the privilege of meeting McGowans parents Finlay and Judy McGowan. You could not ask for a more hospitable couple. Finlay told me about a Canadian bull, AWL Polar 8R, he purchased from Archie Londry in Manitoba. Finlay told me AWL Polar was one of the best bulls they had in their herd.

Archie Londry was breeding cattlemens cattle in the 80s when the rest of Canada was breeding for frame and the show ring, Finlay said. Last time he was in the U.K., Londry was asked his opinion on a cow who won a show a cow of at least a ton with a calf at foot. He said: Well, I guess her calf isnt going to fetch enough in the sale barn to see her through the winter.

I think in our search for progress we sometimes forget the basic principles, Finlay told me. A cow has to rear a decent calf every year one that will leave enough to see the cow through the next winter plus a bit of profit. Increasingly shes going to have to do that without much help, Finlay added.

Wise words from a wise man! Thank you, Finlay.

All in all, a great year to visit with beef producers across our great country and back in the country my grandfather came from. We raise the greatest beef in the world but theres always an opportunity to learn from beef producers the world over.

McKinley Hereford Ranch of Medicine Hat, Alta., won the Top Pen of 10 Hereford Steers at the 23rd Annual British Breed Rancher Calf Sale at Balog Auction Market, Lethbridge, Alta., on October 22. The Top Pen of 10 Crossbred Steers was awarded to Clark and Judy Tucker of Williams Lake, B.C. Norm and Diana Woods of Lac La Hache, B.C., won the Top Pen of 10 Black Angus Steers, and Bill and Travis Duncan of Warner, Alta., took the honours for the Top Pen of 10 Red Angus Steers.

The judging panel awarded the Top Liner Load to three outfits: Denver and Rod Bevans of Cardston, Alta.; Ken and Tyler Haraga of Skiff, Alta.; Brent and Kevin Smith of Champion, Alta.

The Gelbvieh National Junior Show was held in conjunction with the national Gelbvieh show at Farmfair International. It included events such as marketing, judging, photography and grooming done in a format that kids could participate in whether they were able to attend the show or not. Winning junior aggregate was Amber Spray and senior aggregate was Avary Hickman. Congratulations ladies! Thank you to the Canadian Gelbvieh Association, the Man./Sask. Gelbvieh Association, and the Alta./B.C. Gelbvieh Associations for their sponsorship of the event. Congratulations to the following champion exhibitors at the CGA National Gelbvieh show at Farmfair:

Avary Hickman being presented with her buckle by Jessica Pearson.photo: Supplied

The 2018 winners of the Hereford Champion of the World, sponsored by Champion of the World Genetics and Marketing, were recently announced at Farmfair International in Edmonton. The 7th annual competition featured 1,000 champion bulls and females from 77 countries and represented 16 breeds of beef cattle.

The 2018 Hereford Miss World winner was RVP 106A CAMEO GIRL 45C, and is owned by Glenlees Polled Herefords of Arcola, Sask. She qualified by winning the 2018 Canadian Western Agribition. This marks the sixth time a Canadian female has won the competition.

The 2018 Hereford Champion Bull was MLL 10Y ROCKY 225D from MJT Cattle Company, Edgerton, Alta. He also qualified for the world competition by winning the 2018 Canadian Western Agribition.

Cole and Jill Harvie of Olds, Alta., will be participating in next years competition as official judges along with Alejandro Costa from Uruguay, Tom Baker from Australia and Robin Irvine from Northern Ireland.

Continue reading here:
Checking out beef cattle operations in the UK - Canadian Cattlemen

SANTA ANA, Calif.--(BUSINESS WIRE)-- BLS Pharma, Inc. filed a complaint late last month against Genetronics, Inc. and Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Case No. 30-2019-01119045, for breaching a contract to supply a needle-free injection system that BLS Pharma was using to develop a drug-device combination (DDC) for testosterone replacement therapy.

Testosterone replacement therapy is a multi-billion-dollar market primarily used to treat male hypogonadism, a condition in which the body fails to produce enough testosterone. It is also a necessary treatment for transgender individuals transitioning and on lifetime hormone therapy from female to male.

Testosterone replacement therapy can make a significant difference for those in need of treatment. Our product would have allowed users to administer their treatments from the comfort of their own homes using a virtually painless needle-free system, said Mark Logomasini, President & CEO of BLS Pharma.

The shareholders of BLS Pharma previously developed the needleless injector technology, called Zetajet, and sold the intellectual property rights for it to Inovio and Genetronics, with the condition that Genetronics would execute a license and supply agreement to supply Zetajet units to BLS Pharma upon request. Under the agreement, BLS Pharma ordered 25,000 Zetajet units to prepare for its clinical trials on the DDC and was assured that the order was in process.

In September, BLS Pharma and Genetronics discussed the logistics of the syringe supply, and BLS Pharmas plan to offer the product for patients with hypogonadism and as a treatment for transgender males. The next business day, Inovio and Genetronics informed BLS Pharma they would not be supplying the syringes. This breach of contract eliminated BLS Pharmas ability to bring the DDC to market.

We are disappointed that we cannot offer this solution for male hypogonadism and to the transgender community, who have historically been marginalized by the medical and pharmaceutical community, stated Logomasini.

The testosterone treatment market is valued at 1.3 to 1.8 billion dollars annually. BLS Pharmas lost profits due to the breach of contract are estimated to be at least $72,900,000. All media inquiries should be directed to Jason Hartley of the Hartley LLP law firm at (619) 400-5822. For a copy of the complaint, email karen@fullkorrpress.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005928/en/

Excerpt from:
BLS Pharma Alleges Inovio's Breach of Contract Obstructed Ability to Deliver Testosterone Replacement Therapy for Hypogonadism and the Transgender...

Testosterone replacement therapy (TRT) is a class of hormone replacement therapy in which androgens, often testosterone, are replaced. Testosterone replacement therapy (TRT) is an FDA-approved medical treatment for men of any age who have low testosterone, a hormone necessary for male sexual development. Testosterone deficiency, also referred to as hypogonadism, is a common problem among men aged between 40 and 79 years, with some studies stating that nearly 30% of all men worldwide are affected by hypogonadism. As the incidence of testosterone deficiency increases, it is expected that the demand for TRT will also show a simultaneous increase.

Get Sample copy of this Report @:

http://www.a2zmarketresearch.com/sample?reportId=56158

Top Key Players covered in this Report includes: AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals.

The report evaluates the figures of the global Testosterone Replacement Therapy market and presents reliable forecasts as to the markets growth prospects over the coming years. The historical development trajectory of this market is examined in the report, offering solid factual support to the analysis and estimations presented in the report. The geographical and competitive dynamics of this global market are also presented in the report, helping deliver a comprehensive picture of the market.

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Testosterone Replacement Therapy market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Testosterone Replacement Therapy market

Get Upto 30% Discount on first Purchase of this report @:

http://www.a2zmarketresearch.com/discount?reportId=56158

As the global Testosterone Replacement Therapy market is segmented based on various parameters, an in-depth classification of the market is also mentioned; elements impacting the markets growth are studied in detail to understand the report precisely. Moreover this, profiles of some of the leading players operating in the global Testosterone Replacement Therapy market are included in the report. Using SWOT analysis, their weaknesses and strengths are analyzed. It helps the study deliver visions into the opportunities and threats that companies may face during the forecast period.

Reason for buy this market report?

For More Information, Visit @:

http://www.a2zmarketresearch.com/enquiry?reportId=56158

Table of Contents

Global Testosterone Replacement Therapy Market Research Report 2020-2025

Chapter 1 Testosterone Replacement Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Testosterone Replacement Therapy Market Forecast

Conclusion: This exclusive report will provide you a clear view of each and every fact of the Testosterone Replacement Therapy market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Read more from the original source:
Massive Growth of Testosterone Replacement Therapy Market by 2025 with Top Key Players like AbbVie, Endo International, Eli lilly, Pfizer, Actavis...

LYON, France, Jan. 7, 2020 /PRNewswire/ --genOway, a public company and leader in developing genetically modified research models, today announced an important milestone in extending its strategic alliance with Merck, a leading science and technology company and leader in genome editing.

In December 2018, genOway acquired from Merck exclusive worldwide rights on its foundational CRISPR/Cas9 portfolio in the rodent field (all applications involving rodent cells or animals). Today, the two companies have further strengthened their collaboration by entering into an additional license providing genOway with non-exclusive rights to commercialize the development and use of all other animal cell models for its customers' internal research uses as well as commercial exploitation.

"We are delighted to extend our relationship with Merck. The Merck IP is growing and broadening. Merck is now recognized as a leading provider of foundational CRISPR IP. This additional license will enable genOway to serve our customers better, by offering them broad and versatile solutions and the necessary intellectual property rights to help accelerate their research," says Alexandre Fraichard, founder and Chief Operating Officer of genOway.

Both Merck and genOwayhave identified research fields where they can combine their respective technologies and expertise to develop and validate new CRISPR/Cas9-related products and solutions. Merck's patented CRISPR integration technology isa strong entry point through which innovation can be developed and launched.

About genOway

genOway (Euronext Growth: ALGEN; ISIN: FR0004053510) is a biotechnology society that operates in 28 countries in Europe, Asia and North America, and more than 260 research institutes and 80 biopharmaceutical companies. genOway's development is based on a broad and exclusive technology platform, as well as on strong intellectual property rights, combining patents and licensing agreements. The company has signed many commercial contracts with the leaders of the pharmaceutical industry (BMS, Janssen, Novartis, Pfizer, etc.), and with the most prestigious academic research centers, including the King's College and the University of Manchester in England; Harvard, Caltech and the National Institutes of Health in the United States; the Pasteur Institute in France; the German National Genome Research Network and the Max Planck Institute in Germany.

http://www.genOway.com

Logo - https://mma.prnewswire.com/media/1057708/genOway_Logo.jpg

Contact: Sandrine Carteaulicensing@genoway.com+33-43-76-54-100

SOURCE genOway

https://www.genoway.com

See the original post:
genOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Their Partnership to All Animal Cell Models - PRNewswire

When I saw the news that He Jiankui and colleagues had beensentenced to three years in prisonfor the first human embryo gene editing and implantation experiments, all I could think was, How will we look back at what they had done in 100 years?

I imagine that the scientists, medical doctors, and biotechnologists reading this essay will almost unanimously proclaim that He Jiankui will never be viewed in a positive way. What they fail to see is that societal ethics change, especially over long time frames.

In the next 100 years, thousands of edited embryos will be implanted and become children. I believe that embryo editing and implantation will someday be viewed much as how IVF is viewed today. When a human embryo being edited and implanted is no longer interesting enough for a news story, will we still view He Jiankui as a villain?

I dont think we will. But even if we do, He Jiankui will be remembered and talked about more than any scientist of our day. Although that may seriously aggravate many scientists and bioethicists, I think he deserves that honor.

Read full, original post: CRISPR babies scientist He Jiankui should not be villainized or headed to prison

Continued here:
Viewpoint: In 100 years, we'll be honoring controversial CRISPR scientist He Jiankui - Genetic Literacy Project

ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top conference on Thursday, January 9, 2020, at 1:10 p.m. ET.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit http://www.crisprtx.com.

Investor Contact:Susan Kimsusan.kim@crisprtx.com

Media Contact:Jennifer PaganelliWCG on behalf of CRISPR347-658-8290jpaganelli@wcgworld.com

More here:
CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference - Yahoo Finance

The Insight Partners dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology is a simple but powerful tool for genome editing. This tool enables life science researchers to easily edit DNA sequences and modify gene function. It has many potential applications include correcting genetic defects, treating and preventing the spread of diseases and improving crops. By delivering the CRISPR enzyme Cas9 nuclease coupled with synthetic guide RNA (gRNA) into a cell, the cells genome can be cut at a desired location, that allows existing genes to be removed or add new ones.

Increasing usage of CRISPR systems in microbiology, growing government and private investments on research and development of genome editing, rising prevalence of genetic disorders, and increases application of CRISPR/Cas9 technology to improve crop production drives the global CRISPR technology market. However, ethical issues associated with CRISPR and lack of skilled personnel restrain the global CRISPR technology market over the forecast period.

Download a sample report Explore further @ https://www.theinsightpartners.com/sample/TIPRE00002853

Top Dominating Key Players:

The global CRISPR technology market is segmented on the basis of product and services, application, end user. Based product and services, the market is segmented as, enzymes, kits, services and others. The CRISPR technology market is categorized based on application into, genetic engineering, cell line engineering and others. Based on end user, the CRISPR Technology market is classified into biotechnology & pharmaceutical companies, contract research organizations (CROS), and academic & government research institutes.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global CRISPR Technology market based product and services, application, end user. It also provides market size and forecast till 2027 for overall market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The CRISPR Technology Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 countries globally along with current trend and opportunities prevailing in the region.

North America held over major share in the CRISPR Technology market in 2017 owing to significant research carried out in order to develop novel therapeutics for disease targeting and high adoption of genome editing technique for germline modifications. North America is expected to collectively contribute towards the growth of CRISPR Technology market owing to the presence of major market players and also the development of technologically advanced products of CRISPR technology is expected to influence the CRISPR technology market growth.

Make an Enquiry of report for Discount @ https://www.theinsightpartners.com/discount/TIPRE00002853

Reasons to Buy the Report:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

The Insight partners,

Phone: +1-646-491-9876Email:[emailprotected]

Read more:
CRISPR Technology Market Emerging Trends to Achieve Significant Growth in the Coming Years - Pro News Time

A New Years Eve gift has been granted by the federal government to the University of California its 20th U.S. patent on CRISPR-Cas9 gene-editing technologies. The addition extends a large patent portfolio that is already being used to develop crop and seed breeding and human and animal health.

The new patent is the 18th concerning CRISPR-Cas9 technology granted this year by the University of Vienna and Emmanuelle Charpentier, who co-invented the technology with Jennifer Doudna of UC Berkeley, professor of molecular and cell biology and chemistry. Charpentier is currently the head of the Berlin-based Max Planck Institute for Infection Biology.

2019 has been an incredibly important and successful year in our ongoing efforts to maintain UC as the pioneer of CRISPR-Cas9 Intellectual Property in the United States, said Eldora L. Ellison, CRISPR-Cas9 University Patent Strategist and President of Sterne, Kessler, Goldstein & Fox, an intellectual property law firm. We are inspired by this years USPTO (U.S. Patent and Trademark Office) recognition of the leadership of the Doudna-Charpentier team on CRISPR-Cas9 and look forward to working to grow our portfolio by 2020.

In accordance with the UCs long-standing dedication to developing and applying its proprietary inventions to human enhancement, the university allows non-profit institutions, including academic institutions, to use the groundbreaking CRISPR-Cas9 technology for non-commercial research and educational purposes.

The UC also encouraged the widespread marketing of CRISPR-Cas9 technology through an exclusive license with Berkeley, Californias Caribou Biosciences Inc., which has sub-licensed the patent family to numerous companies around the world. The technology is currently being used to modify cattle, sheep and pig genomes to help fend off disease, create screens for human disease medications, generate updated human and mouse cell lines to help researchers understand and manage these disorders in humans, and manufacture research reagents.

In addition, Caribou licenses the technology for human medical uses to Intellia Therapeutics Inc., specifically cancer treatments, genetic disorders, viral infections and inflammatory diseases. The new patent (U.S. Patent 10,519,467), which proposes a method of generating a genetically engineered cell using CRISPR-Cas9 gene editing, is part of a collection of foreign and domestic patents that includes multiple CRISPR-Cas9 formulations and methods, such as controlling and editing genes and modulating transcription in any environment, even within plant, animal and human cells. The UCs 20 patents are the largest portfolio of CRISPR-Cas9 patents in the U.S. The UC has received notices of allowance for the issuance of five additional patents in early 2020.

Here is the original post:
UC's 20th US patent on CRISPR-Cas9 gene-editing technologies - Health Gazette

NEW YORK, Jan. 7, 2020 /PRNewswire/ --

Report Includes: - An overview of recent advances in stem cell therapies and coverage of potential stem cells used for regenerative advanced therapies

Read the full report: https://www.reportlinker.com/p05835679/?utm_source=PRN

- Discussion on role of genomic and epigenomics manipulations in generating safe and effective treatment options - Identification of autologous and allogeneic cells and their usage in creating advanced therapy medical products (ATMPs) - Information on 3D cell culture and discussion on advances in gene editing and gene programming techniques such as CRIPSR/Cas9, TALEN, and ZINC fingers - Insights into commercial and regulatory landscape, and evaluation of challenges and opportunities for developing autologous and allogenic "off the shelf" solutions

Summary Stem cells are unique in their ability to divide and develop into different cell types that form tissues and organs in the body during development and growth.The stem cell's role is to repair impaired or depleted cells, tissues and organs in the body that are damaged by disease, injury, or normal wear and tear.

Stem cells are found in every organ, but are most abundant in bone marrow, where they help to restore the blood and immune system.

Stem cells may be derived from various sources, including - - Adult stem cells (ASCs): Derived from tissue after birth, these include bone marrow, brain, peripheral blood, skeletal muscle, skin, teeth, heat, gut, liver, ovarian epithelium and testis, as well as umbilical cord stem cells and blood. These cells are currently most widely used for cellbased therapies. Hematopoietic stem cells (HSCs), which are derived from bone marrow, can give rise to red blood cells, white blood cells and platelets, whereas mesenchymal stem cells (MSCs) are derived from the stroma and give rise to non-blood forming cells and tissues. - Human embryonic stem cells (hESCs): Derived from embryos, these include stems cell lines, aborted embryos or from miscarriages, unused in vitro fertilized embryos and cloned embryos. There are currently no clinically approved treatments for embryonic stem cells. - Inducible pluripotent stem cell (iPSCs): These are stem cells generated in the laboratory by reprogramming adult cells that have already differentiated into specific cells, such as liver cells. They are used either for research purposes (e.g., experimental medicine testing toxicity of new drugs) or are under research for potential future clinical use.

Read the full report: https://www.reportlinker.com/p05835679/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/highs-and-lows-of-stem-cell-therapies-off--the-shelf-solutions-300982411.html

SOURCE Reportlinker

Read the original here:
Highs and Lows of Stem Cell Therapies: Off- The-Shelf Solutions - P&T Community

This is a sponsored story

The start of a new year is the perfect time to prioritize self-care and set health and wellness goals, so make 2020 your happiest yet with a new, enhanced version of you. Use this guide to find the doctors, therapists and practitioners that can help you look and feel your best.

When diet and exercise just wont provide the results youre looking for, visit Skiin Anti-Aging Lounge. They offer the only procedure that builds muscle. EMSCULPT has been proven safe and effective by the most reputable scientific methods. The procedure induces strong muscle contractions with Hifem (high-intensity electromagnetic) technology not achievable through voluntary contractions. This builds muscle and creates a sculpted, toned physique. Other services like CoolSculpting and Exilis also help clients reshape their bodies through nonsurgical, noninvasive methods. Skiin is the first and only CoolSculpting advanced education center in the nation. Another first: Exilis is the first and only device to combine radio frequency and ultrasound to tighten skin through heating and cooling.

Your face is the first place to show signs of aging, but there is a way to take back those years. Dr. John Yousif has received several awards for his research in facial aging. He has been practicing plastic and cosmetic surgery for over 30 years and has even pioneered new techniques like the Gortex Midface Lift and the Hyoid Suspension Neck Lift. At both Sier Medi-Spa and Ascension in Mequon, he offers surgical and nonsurgical procedures to reverse the signs of aging. All of the types of facelifts offered are long-lasting and natural looking, leaving clients feeling like a younger version of themselves.

RELATED What Is Man & Woman Of The Year?

Aqua, under the direction of Dr. Christopher Hussussian, is a full-service salon, spa and med spa offering a wide range of services in a luxurious setting on Pewaukee Lake. Whether you are hoping to change the way you look or feel or both Aqua has a solution to enhance your skin and hair for both body and face. New services for the new year include hair restoration for both men and women using PRP (platelet-rich plasma) with biotin and a new weight-loss program using the HCG hormone. They also offer advanced laser hair removal, Clear Lift skin tightening, ThermiVa and CoolSculpting, a popular nonsurgical fat cell reduction with lasting results. A consultation can help you decide what services would work best to achieve a healthier, happier version of yourself.

Serving the Lake Country area, Dr. Tom Stamas is helping people put their best face forward, one smile at a time. He specializes in smile design, a full dental restoration and reconstruction for those suffering from tooth damage or loss, or for those looking to fix crooked, worn or yellowed teeth. During your personalized consultation, Stamas and his team will help you select which treatments will bring your smile to life. Dental treatments like bridges, dental implants, crowns and state-of-the-art diagnostic tools are all available to restore the health, function and appearance of your smile. Youll feel good about the natural-looking results, and your self-esteem will get a boost too.

What if you could use undesired fat from your belly to get rid of the bags under your eyes? Sounds too good to be true, right? Anew Skin and Wellness has a procedure that is done right in the office with long lasting results. The nano-fat transfer removes a small amount of fat with micro liposuction. That fat is harvested for re-injection to the appropriate areas of the face, neck, earlobes, hands and thighs. It can also be used to plump thin lips, smooth cellulite and scars and restore skin elasticity. The nano-fat transfer is safe, effective, economical and helps clients look their best. The in-office procedure provides long-lasting results because the bodys stem cells can turn the aging skin into new, rejuvenated skin. Its the natural way to tighten and smooth skin, allowing you to turn back the clock without a surgical face- or neck-lift.

RELATED Local Homebuilders Talk About the Hottest Design Trends in Milwaukee Right Now

Dr. Arvind Ahuja has provided neurosurgical and endovascular care in southeastern Wisconsin for more than 20 years for brain, spine, artery and peripheral nerve conditions. Whether patients come to Neurosurgery and Endovascular Associates for neck and/or arm pain, back and/or leg pain or headache, the first step is always diagnostic testing to determine the cause of the pain, rather than just treating the symptoms. Often through treatments like medication, steroid injections, physical therapies and if need be surgery, patients achieve improved functioning and long-term relief. Ahujas specialized training in the nervous system is incredibly effective in treating spinal conditions, and his treatments give patients the opportunity to live a happier and morefunctional life.

Continued here:
How These Practitioners Can Help with New Year, New You Goals - Milwaukee Magazine

In high school Aaron Sandoval became obsessed with Deadpool, Marvels comic character who has accelerated healing and regenerative powers.

Sandoval has turned in his superhero cape for a lab coat in medicine by working with reparative methods for the human body. And now, hes received a national award that will allow him to do that.

Sandoval, a 21-year-old UF biology senior, was selected for the Marshall Scholarship, which gives students in the U.S. a chance to pursue their graduate studies in the United Kingdom, all expenses paid. He is the second Marshall scholar in UFs history, following Steven Robinette in 2009.

Sandoval was one of 46 students chosen out of over 1,000 applicants across the U.S.

The Marshall Scholarship Program was created in 1953 to thank the U.S. for helping the U.K. after World War II under the Marshall Plan, which was the U.S.s way of helping European economies after the devastation of the war, according to the programs website.

It still hasnt really sunk in yet, Sandoval said. Im happy to have won it.

Sandoval said in his two years at the University of Cambridge and Kings College London hell study biochemistry and focus on the transfer of stem cells from the lab to the patients so they can understand what cells are being used to help them.

Sandoval has collaborated with UF faculty members like Malcolm Maden, a professor in UFs Cancer and Genetics Research Institute. Sandoval and Maden worked in a lab with an African spiny mouse, to figure out how stem cells repair parts of the human body like skin tissue.

In 2012, Maden and his research team discovered the African spiny mouses ability to regenerate skin scar free. Maden wrote one of Sandovals letters of recommendation for his application for the scholarship.

Sandoval said if the mouses regeneration of skin cells could be translated to humans, then a humans wounds could completely heal rather than scar.

Sandoval didnt have the opportunity to do research in high school and wanted to learn more at the university level, so he decided to take Madens lab.

Maden said Sandovals uniqueness stems from his intelligence, drive and ability to interact with different kinds of people.

Hes behaved like a dynamic scientist, not like an undergrad, he said. Completely amazing, totally unique guy.

Sandoval said he feels fortunate to have won the award and to have so many people who helped him get to this point.

I couldnt have done it without the support of family, friends, mentors, he said. It took a whole village to win this thing.

Contact Emma McAvoy at[emailprotected]. Follow her on Twitter@EmmaMcAvoy1.

Continued here:
UF student chosen for the Marshall Scholarship, will pursue Masters degrees in United Kingdom - The Independent Florida Alligator

Welcome to Try Before You Buy, a monthly series where we talk about the pricey beauty products and in-office treatments that are getting major buzz and give our honest feedback. This month, our Senior Beauty & Fashion Editor, Pia Velasco, talks about theAugustinus Bader cream that has changed her skin.

As a beauty editor, Ive tried hundreds (and maybe even thousands) of skincare products since starting my career seven years ago. There have been creams that promise to give me skin as soft as babys bum, serums that pledge to erase all signs of dark spots, face masks that swear theyll make my skin so radiant that itll blind my enemiesand guess what, most of them fell through on their promises. As such, Ive become skeptical when a brand tells me that their product is life-changing and that there isnt anything like it on the market. So when I met Professor Augustinus Bader, the director of the Applied Stem Cell Biology and Cell Technology at the University of Leipzig in Germany, earlier this year and he and his team told me about his epigenetic skincare line that changes the skin to the point of altering DNA, I have to admit that I did mentally raise an eyebrow.

However, I had heard about epigenetic skincare before and was fascinated by the science behind it. Essentially, epigenetics refers to the naturally occurring biological modification process of the DNA thats influenced by the environment and lifestyle patterns. For example, if you have a healthy diet and exercise on the regular, your genetic coding will eventually change to be healthier, and youll be able to transfer those healthy genes onto your offspring. Epigenetic skincare is the same conceptif you train your skin cells to be healthy, your skins DNA will change. Needless to say,I was curious to try it, and when a fellow beauty editor friend told me that she stopped using all of her skincare products after trying the Augustinus Bader The Rich Cream, I went from being curious to being eager to try it.

A quick background on my skin. Ive always had acne-prone skin, and because of my medium skin tone, Im also very prone to hyperpigmentation. Most of the skincare products I use target my acne concerns, but I also go ham on texture-refining products in hopes that one day Ill achieve glass-like skin. Im used to looking at ingredients that target specific skincare concerns (salicylic acid for acne, retinol for anti-aging, vitamin C for brightening, etc.), and for the first time, I was using a product that claimed that it would address all my concerns at once. Because of the way epigenetic skincare works, instead of targeting just one skincare concern, the product tells skin cells to be healthy, which in turn helps skin be the best version of itself.I know it sounds too good to be true, and while it may not work for everybody, holy shit it worked wonders for me.

Courtesy of Augustinus Bader

I started testing out the cream the way I approach all my beauty testing, I did a test-drive on half my face. On the left side of my face, I continued to use the products that were already in my arsenal, and on the right side of my face, I used the Augustinus Bader cream and nothing else. After about two weeks I started seeing a shiftmy acne wasnt working up, my skin texture was a lot more smooth, and it just looked overall healthier. I quickly tossed my other products and switched over to using The Rich Creamevery day. After a while, my skin started balancing out and both looked and felt a whole lot better. Now, Im not saying this product is magicbut Im also not saying that its not.

Im currently testing a whole new array of skincare products for the upcoming HelloGiggles Beauty Crush Awards (stay tuned!), and so Ive had to sacrifice the left side of my face to test new products (I switch off between sides). As a result, my skin has started to shift back into its old ways, with a resurgence of blemishes, dark spots, and uneven texture as I test out new formulas. But the right side of my face is still in A+ condition.

Sure, this product is definitely on the pricier side, but its a product that I can say with full confidence that I would actually buy if I wasnt a beauty editor. (Full disclosure: I receive a lot of free products from beauty brands, and Ive only bought about a handful of products with my own money since working in the business.) For me, getting my ideal skin has always been a battle, and Im so happy to have finally found a product that works magic for me, which is why I was excited to learn that the brand recently launched a body cream as well.

Courtesy of Augustinus Bader

Its important to remember that body care requires skincare too, after all, we do have skin on our bodies. The Augustinus Bader body cream fulfills the basic requirement of moisturizing skin, but what makes this anti-aging body product stand out is that it uses its epigenetic technology to target and treat stretch marks and cellulite with continued use. Now, I havent used it long enough to speak to its long-term effects, but I can say that its fast-absorbing formula does make my skin feel baby soft and look way smoother than it did before. Also, Im typically very good about sharing my beauty products with others, but when my boyfriend asked if he could use this cream I may or may not have told him Id put a curse on his ancestors if he dared. Nothing gets in the way of me and my Augustinus Bader products.

Read the original here:
The viral Augustinus Bader rich cream has completely changed my skin for the better - Yahoo Lifestyle

The latest lifestyle, fashion and travel trends

A high-end bio-beauty boom is in full bloom thanks to a host of revolutionary brands set on changing the face of modern skincare. These are the five to know...

Hailing from the Napa Valley, where founder April Gargiulo spent two years researching and developing her Holy Grail skincare products using the same meticulous approach her family took to their fine wine business, Vintners Daughter champions just two products that promise dramatic, multi-correctional results using some of the worlds most active organic and foraged botanicals. The original Active Botanical Serum (175) is hailed as the face oils to end all face oils and is built around the brands signature Phyto Radiance Infusion. This process starts with consciously grown whole plants such as calendula and super green alfalfa, known in ancient times as the foods of life, which undergo a methodical three-week long extraction to glean every last drop of their nutritional benefits. Just five drops using the brands 30-second Push/Press Method of application promises to deliver visible radiance, brightness and unparalleled nourishment particularly when used in conjunction with its preparatory Active Treatment Essence (210) (goop.com).

The undisputed Queen of Green, Tata Harper is a pioneer of the farm-to-face beauty movement with all-natural formulations handcrafted in the brands laboratory in Vermont and bottles stamped with a code to trace how fresh your product is and who it was made by. The beauty editors favourite is going one step further with the launch of its Supernaturals 2.0 line of six products boasting 155 ultramodern green ingredients from 46 countries and of course, no synthetic chemicals. The Elixir Vitae Serum (391) alone boasts 34 new radical engineered ingredients from 25 countries, including kelp polymers from France developed to target cellular ageing. Other highlights from the range include the Concentrated Brightening Serum (257), which contains 24 ingredients to hydrate, 17 to reduce wrinkles, 15 to brighten and 13 to even skin tone, and the Boosted Contouring Serum (257), designed to lift, firm and restore youthful elasticity with a combination of Edelweiss stem cells and skin revitalising pomegranate. (tataharperskincare.com)

The brainchild of cosmetologist Anna Buonocore and naturalist Jeanette Thottrup, Seed To Skin believes that effective skincare is threefold. Firstly, that wild ingredients foraged from the land and sea used in conjunction with those sourced from its organic Tuscan farm are among the most potent nature has to offer. Secondly, that just like feeding your body skin requires a healthy, balanced diet and formulas that neither starve nor overload with any one element. Finally, that the most effective absorption relies on a precise mix of perfectly-sized molecules to ensure each ingredient is delivered exactly where it needs to go. As a result, its award-winning product line is loaded with game changers try The AlcheMist Super Active Serum Spray (145) to feed your skin a nutrient-rich drink whenever it needs a boost, or the Black Magic Detoxifying Oxygen Therapy Mask (119) which contains activated charcoal and volcanic clay for a one-stop facial in a jar (libertylondon.com).

(Wildsmith )

Inspired by the arboretums progressive approach to cultivation at Hampshires Heckfield Place and named after its mastermind William Walker Wildsmith, this ethical crafted-in-England skincare brand is designed for those who desire natural products but demand clinical results. Exclusive to Harrods beauty halls, the hero additions to its product line-up include the Platinum Booster (175) a powerful skin-firming treatment powered by encapsulated oxygen and moss cell cultures and a reviving, collagen-boosting Copper Peptide Cream and Serum Duo (150) which delivers a luminous finish to your complexion and comes in a compostable mycelium box (wildsmithskin.com; harrods.com).

After turning to flower arranging as a weekly dose of mindfulness, beauty entrepreneur Kelly S Chung endeavoured to harness the healing power of nature or Flower Therapy, as she has coined it in another form; and Femmue was born. Fusing K-beauty innovation with a clean beauty ethos and the cellular energy of plants, the camellia flower is at the heart of the range and renowned for its antioxidant and restorative qualities. The Divine Camlia Facial Oil (100) is the purest form with 99.8 per cent camellia seed oil, while other must-try products in the line include the bestselling Flower Infused Fine Mask (40) formulated with camellia petals, geranium oil and cactus extract and the lavender-loaded Brilliant Cleansing Oil (73) (net-a-porter.com).

Read the original here:
Super Naturals: the high-tech natural beauty brands changing the face of modern skincare - Evening Standard

Have you ever gone to look for something on Amazon and suddenly felt too overwhelmed by all the options? Yeah, me too. I love to have choices, but sometimes I need more information in order to make a smart buy. This is particularly true for beauty products the selection seems endless.

As a shopping editor, my sole job is to hunt for the best products customers should know about when it comes to beauty. I take that job very seriously, since we're literally using these items on our bodies. That's why I love trying new things from Amazon, because they often come with hundreds of customer reviews. I know it's a purchase I can feel good about after doing my research. I've rounded up the bestselling beauty products our editors have reviewed and bought themselves. Check out everything, and give something new a try.

Excerpt from:
22 Beauty Items From Amazon That Have Changed Our Editors' Lives Their Reviews Prove It - POPSUGAR